Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 14/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | UBE2M | P61081 | 1/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708830 | 0.91 | BCHE (0.52) | BCHERAD52LMNASMN1; SMN2 | |
| SCHEMBL1708821 | 0.81 | BCHE (0.51) | BCHELMNAMAPTSMN1; SMN2 | |
| SCHEMBL1708826 | 0.80 | BCHE (0.63) | BCHE | |
| SCHEMBL1708823 | 0.80 | BCHE (0.51) | BCHEKDM4E | |
| SCHEMBL1708825 | 0.77 | BCHE (0.48) | BCHEKDM4EMAPT | |
| SCHEMBL1280000 | 0.76 | RAD52 (0.51) | RAD52KDM4EMAPT | |
| SCHEMBL1708831 | 0.76 | BCHE (0.59) | BCHEMAPT | |
| SCHEMBL1709604 | 0.75 | BCHE (0.45) | BCHEMAPTSMN1; SMN2 | |
| SCHEMBL1709533 | 0.75 | BCHE (0.45) | BCHEMAPT | |
| SCHEMBL1708829 | 0.73 | BCHE (0.44) | BCHELMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8287969-B2 | Isosorbide derivatives and liquid crystal displays comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-10-16 | — | — | US | disclosed |
| US-8287969-B2 | Isosorbide derivatives and liquid crystal displays comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-10-16 | — | — | US | disclosed |
| US-20120086902-A1 | ISOSORBIDE DERIVATIVES AND LIQUID CRYSTAL DISPLAYS COMPRISING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-04-12 | — | — | US | disclosed |
| US-20120086902-A1 | ISOSORBIDE DERIVATIVES AND LIQUID CRYSTAL DISPLAYS COMPRISING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120086902-A1 | ISOSORBIDE DERIVATIVES AND LIQUID CRYSTAL DISPLAYS COMPRISING THE SAME | CX3CR1, CBX3, YBX3 | BCHE 1786/4885RAD52 3660/4885UBE2M 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.